IAG will Attend Biotech Week / JPM in San Francisco, USA, 8-11 January 2024

IAG will Attend Biotech Week / JPM in San Francisco, USA, 8-11 January 2024

A Powerful Partnership with AVM Biotechnology: Hope and Progress

IAGs’ bio-partnering  team will be attending biotech week in San Francisco.  IAG’s CEO, Dr. Olga Kubassova will attend JP Morgan meeting and our team of Bio-Partnering Directors will be attending Biotech Showcase and satellite events in San Francisco, USA, from January 8-11 January, 2024.

“Today’s volatile market demands laser-focused development strategies, leveraging technology and A.I. to disrupt the old paradigm of drug development. At IAG, we’ve seen this demand surge, and in 2023, we defied market headwinds, securing many high-impact partnerships with pharma and biotech giants. We thrive to deliver solutions that de-risk, accelerate, and illuminate biotech path to market. Getting a novel clinical asset through a successful partnership or the registration is our passion and mission,” said Dr Kubassova, IAG’s CEO.

Bio-Partnering is an independent investment division of IAG. We are building a diversified investment portfolio of innovative life science companies at various stages of clinical development. By bringing strategic collaborators and smart investments, we support their drug development efforts through clinical trials to market entry.

Our biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships.

We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, rheumatology, musculoskeletal, immunology markets.

About Image Analysis Group (IAG):

At the forefront of AI-powered drug development and precision medicine, IAG harnesses the potential of medical imaging and the cutting-edge Dynamika™ platform. We redefine clinical development, offering early drug efficacy assessments, strategic patient recruitment, and predictive analysis. With a pioneering bio-partnering approach, we expand the horizons of asset development through risk-sharing financing and partnering models. ia-grp.com

Learn more:  ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin